Guangzhou drugmaker focused on children's medicines (cold, flu, digestive, skin) and chronic-disease drugs, with a gout drug in development.
Guangzhou drugmaker focused on children's medicines (cold, flu, digestive, skin) and chronic-disease drugs, with a gout drug in development.
Sells prescription drugs to hospitals and pharmacies in China, with a catalogue split between children's medicines for colds, flu, digestion and skin conditions and drugs for chronic diseases such as cardiovascular, kidney and liver illness. Its growth bet is AR882, a gout drug in development that has a US fast-track designation.
Moat: narrow (regulatory licence, brand). Many registered drug approvals, some on national reimbursement lists, with a pediatric focus.
Headquarters: Guangzhou, China · Founded: 2002 · Employees: 1,294
Size ApicHope Pharmaceutical (300723.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.70B, the 1349th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥25.71 on 18 Nov 2026.
Performance Over six months the shares fell 35.9%, against +1.7% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 28.3% over the last twelve months (peer median +13.8%); the operating margin is -50.2% (peer median 9.9%).
Valuation It trades at 22.0× forward earnings against a peer median of 19.7× (6th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is -11%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 14.3 points below its cost of capital (8.5% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥735M | CN¥926M | CN¥1.44B | CN¥2.47B | CN¥2.25B |
| Revenue growth | — | -36% | -42% | +10% | — |
| Gross profit | CN¥443M | CN¥404M | CN¥735M | CN¥1.88B | CN¥1.86B |
| EBITDA | n/a | -CN¥94.7M | -CN¥63.4M | CN¥437M | CN¥408M |
| Net income | CN¥181M | -CN¥338M | -CN¥540M | CN¥185M | CN¥291M |
| Free cash flow | CN¥513M | -CN¥70.6M | -CN¥862M | CN¥133M | -CN¥114M |
| Capital expenditure | CN¥94.7M | CN¥127M | CN¥320M | CN¥334M | CN¥606M |
| Total debt | CN¥2.02B | CN¥2.12B | CN¥1.75B | CN¥825M | CN¥1.22B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ApicHope Pharmaceutical 300723.SZ | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% |
| Humanwell Healthcare (Group) 600079.SS | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300723.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.3% | +0.3% | 4th lowest of 21 |
| 6-month return | -35.9% | +1.7% | 3rd lowest of 20 |
| Distance from 52-week high | -54.1% | -34.3% | 4th lowest of 21 |
| Revenue growth (TTM) | -28.3% | +13.8% | 3rd lowest of 20 |
| Operating margin | -50.2% | 9.9% | 4th lowest of 20 |
| Forward P/E | 22.0× | 19.7× | 6th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 11.3% | 18.4% | 8th least demanding of 16 |
| Growth delivered (Del g) | -11.0% | +9.9% | lowest of 16 |
| Hurdle (Req g minus delivered) | +22.2 pp | +1.5 pp | 3rd most demanding of 16 |
| ROIC minus cost of capital | -14.3 pp | -0.8 pp | 5th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |